JP2019533652A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533652A5
JP2019533652A5 JP2019517257A JP2019517257A JP2019533652A5 JP 2019533652 A5 JP2019533652 A5 JP 2019533652A5 JP 2019517257 A JP2019517257 A JP 2019517257A JP 2019517257 A JP2019517257 A JP 2019517257A JP 2019533652 A5 JP2019533652 A5 JP 2019533652A5
Authority
JP
Japan
Prior art keywords
subject
cdk1
clk2
cell
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019517257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533652A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/054442 external-priority patent/WO2018064545A1/en
Publication of JP2019533652A publication Critical patent/JP2019533652A/ja
Publication of JP2019533652A5 publication Critical patent/JP2019533652A5/ja
Pending legal-status Critical Current

Links

JP2019517257A 2016-09-30 2017-09-29 がんを処置するための二重clk/cdk1阻害剤 Pending JP2019533652A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402876P 2016-09-30 2016-09-30
US62/402,876 2016-09-30
PCT/US2017/054442 WO2018064545A1 (en) 2016-09-30 2017-09-29 Dual clk/cdk1 inhibitors for cancer treatment

Publications (2)

Publication Number Publication Date
JP2019533652A JP2019533652A (ja) 2019-11-21
JP2019533652A5 true JP2019533652A5 (https=) 2020-11-12

Family

ID=61760971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517257A Pending JP2019533652A (ja) 2016-09-30 2017-09-29 がんを処置するための二重clk/cdk1阻害剤

Country Status (5)

Country Link
US (2) US10722515B2 (https=)
EP (2) EP4086257A1 (https=)
JP (1) JP2019533652A (https=)
CN (2) CN114149432B (https=)
WO (1) WO2018064545A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
CN114149432B (zh) 2016-09-30 2024-07-05 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂
WO2020006115A1 (en) * 2018-06-26 2020-01-02 Betty Tam Methods of treating cancer using a clk inhibitor
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
CN113384703B (zh) * 2021-06-21 2023-03-10 深圳市第二人民医院(深圳市转化医学研究院) Dhx34基因的表达抑制剂在制备抑制肝癌细胞转移和侵袭的药物中的应用
CN120289460A (zh) * 2024-01-09 2025-07-11 中国科学院合肥物质科学研究院 含有嘌呤环的化合物及其用途
WO2025243082A2 (en) * 2024-05-24 2025-11-27 The Chinese University Of Hong Kong Covalent protein-protein interaction inhibitor against srpks

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
BR9611157A (pt) * 1995-11-01 1999-03-30 Novartis Ag Derivados de purina e processos para sua preparação
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
CA2394654A1 (en) * 1999-12-17 2001-06-21 Manfred Weigele Proton pump inhibitors
US20020103161A1 (en) * 1999-12-17 2002-08-01 Manfred Weigele Novel heterocycles
ATE345349T1 (de) * 1999-12-17 2006-12-15 Ariad Pharma Inc Purinderivate
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2009085226A2 (en) * 2007-12-21 2009-07-09 Sirtris Pharmaceuticals, Inc. Inhibitors of cdc2-like kinases (clks) and methods of use thereof
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
WO2013144532A1 (en) 2012-03-30 2013-10-03 Astrazeneca Ab 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
WO2013171473A1 (en) 2012-05-15 2013-11-21 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
WO2014160183A1 (en) * 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
UA115388C2 (uk) * 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2017210138A1 (en) 2016-05-31 2017-12-07 The J. David Gladstone Institutes In vitro methods of differentiating stem cells into neurons and neurons generated using the same
CN114149432B (zh) * 2016-09-30 2024-07-05 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂

Similar Documents

Publication Publication Date Title
JP2019533652A5 (https=)
JP2017008088A5 (https=)
JP2018517686A5 (https=)
CN113767106A (zh) 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途
JP2018536636A5 (https=)
RU2017143776A (ru) Пролекарства альвоцидиба, имеющие повышенную биодоступность
RU2013102398A (ru) Лечение рака крови
JP2015533176A5 (https=)
JP2019510746A5 (https=)
JP2019506392A5 (https=)
JP2016515561A5 (https=)
JP2020514356A5 (https=)
JP2015212268A5 (https=)
JP2018535951A5 (https=)
JP2018535923A (ja) 胆道癌の治療
JP2019501204A5 (https=)
JP2018522045A5 (https=)
JP2016536286A5 (https=)
JP2013527249A5 (https=)
JP2014510729A5 (https=)
CN109952304A (zh) 一类抑制并降解cdk的化合物
JP2018534288A5 (https=)
JP2016529285A5 (https=)
JP2017513908A5 (https=)
JP2015500884A5 (https=)